{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015552","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.527420+00:00","generated_at":"2026-06-24T02:50:56.421925+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxcyte Q2 net loss $48.5M; VAX-24 Phase 2 fully enrolled with topline data expected Oct/Nov 2022","bullets":["Cash, equivalents and investments of $361.4M at June 30, 2022 (vs. $273.1M at Dec. 31, 2021).","R&D expenses $38.5M, up from $17.7M YoY due to VAX-24/VAX-XP/Phase 3 readiness activities.","Net loss $48.5M for Q2 2022 compared to $23.7M in Q2 2021.","Completed enrolment of Phase 2 portion of VAX-24 proof-of-concept study in adults 50-64 (≈800 subjects).","FDA granted Fast Track designation for VAX-24 in adults; topline results expected Oct or Nov 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015552","json":"https://secwatch.observer/filing/0000950170-22-015552.json","markdown":"https://secwatch.observer/filing/0000950170-22-015552.md","text":"https://secwatch.observer/filing/0000950170-22-015552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000095017022015552/0000950170-22-015552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000095017022015552/pcvx-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:50:56.421925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}